Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412164 | 0.84 | ALDH1A1 (0.58) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL9815245 | 0.84 | MAPT (0.58) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL5203012 | 0.81 | ALDH1A1 (0.69) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL486125 | 0.81 | MAPT (0.73) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL5672393 | 0.80 | ALDH1A1 (0.64) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL4348322 | 0.80 | ALKBH5 (0.57) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL11590248 | 0.79 | ALDH1A1 (0.56) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL4399573 | 0.79 | MAPT (0.53) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL2484228 | 0.79 | KMT2A (0.60) | ALKBH5ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL486233 | 0.78 | ALDH1A1 (0.69) | ALKBH5ALDH1A1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486801-A | Synthesis process for continuously preparing Ai Qubo Pa by using 3D printing forming technology | 南京恒通医药开发有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-111518029-A | Continuous production process of eltrombopag | 南京恒通医药开发有限公司 | 2020-08-11 | — | — | CN | claimed |
| WO-2013049605-A1 | PROCESSES FOR THE PREPARATION OF AN INTERMEDIATE IN THE SYNTHESIS OF ELTROMBOPAG | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2013-04-04 | — | — | WO | claimed |
| CN-117486801-A | Synthesis process for continuously preparing Ai Qubo Pa by using 3D printing forming technology | 南京恒通医药开发有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117362233-A | Etrepah ethanolamine impurity and preparation method thereof | 山东新时代药业有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-112645879-B | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11161821-B2 | Process for the preparation of Eltrombopag olamine and its intermediates | AUROBINDO PHARMA LTD. (IN) | 2021-11-02 | — | — | US | disclosed |
| US-20210230120-A1 | An improved process for the preparation of Eltrombopag Olamine and its intermediates | AUROBINDO PHARMA LTD (IN) | 2021-07-29 | — | — | US | disclosed |
| EP-3802651-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ELTROMBOPAG OLAMINE AND ITS INTERMEDIATES | Aurobindo Pharma Limited (IN) | 2021-04-14 | — | — | EP | disclosed |
| CN-112645879-A | Method for synthesizing Eltrombopag by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-111518029-A | Continuous production process of eltrombopag | 南京恒通医药开发有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2002057300-A1 | REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-1223944-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1213965-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| EP-1156804-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001034585-A1 | SEMICARBAZONE DERIVATIVES AND THEIR USE AS THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001021180-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001017349-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BECKMAN CORPORATION (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000035446-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230120-A1 | An improved process for the preparation of Eltrombopag Olamine and its intermediates | THPO, EPOR, F2 | ALKBH5 1267/4885ALDH1A1 1533/4885KMT2A 1643/4885 |
| US-11161821-B2 | Process for the preparation of Eltrombopag olamine and its intermediates | THPO, EPOR, F2 | ALKBH5 1241/4885ALDH1A1 1195/4885KMT2A 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.